Trial Profile

A Phase I/II Clinical Trial of FOLFOX Bevacizumab Plus Botensilimab and Balstilimab (3B-FOLFOX) in Patients With MSS Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Bevacizumab (Primary) ; Botensilimab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Adverse reactions; Therapeutic Use

26 Feb 2025 According to an Agenus media release, company announced data of this trial at ASCO GI 2025
12 Feb 2025 Status changed from recruiting to active, no longer recruiting.
12 Feb 2025 According to an Agenus media release, company announced that the data of this trial will be discussed in presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com